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RESEARCH ARTICLE
National and State-Specific Shingles Vaccination
Among Adults Aged Z60 Years
Peng-jun Lu, MD, PhD,1 Alissa O’Halloran, MSPH,1 Walter W. Williams, MD, MPH,1
Rafael Harpaz, MD2
Introduction: Shingles (herpes zoster) causes substantial morbidity, especially among older adults.
The shingles vaccine has been recommended for people aged Z60 years since 2006. This study
assessed recent shingles vaccination at national and state levels among adults aged Z60 years.
Methods: The 2014 Behavioral Risk Factor Surveillance System data were analyzed in 2015 to
assess shingles vaccination coverage among adults aged Z60 years at national and state levels.
Multivariable logistic regression and predictive marginal models identified factors independently
associated with vaccination.
Results: Shingles vaccination coverage among adults aged Z60 years was 31.8% (95% CI¼31.4%,
32.2%). Among states, shingles vaccination coverage ranged from 17.8% (95% CI¼15.8%, 20.0%) in
Mississippi to 46.6% (95% CI¼44.3%, 48.8%) in Vermont, with a median of 33.3%. Coverage waso25%
in four states and 440% in nine states. For all states, coverage was significantly higher among non-
Hispanic whites compared with non-white races except for Oregon, with coverage differences ranging
from –33.2% in the District of Columbia to 0.9% in Oregon and a median of –16.0%. Characteristics
independently associated with vaccination were age, race/ethnicity, sex, education, employment status,
household income, region, perceived health status, health insurance status, personal healthcare provider,
routine checkup status, and whether reporting that cost was a barrier to seeing a doctor.
Conclusions: Coverage varied dramatically by state. State-level comparisons may aid in designing
tailored intervention programs through sharing of best practices. Strategies are needed to mitigate
financial barriers for both provider and patients, improve awareness, and increase provider
recommendation of the vaccine.
Am J Prev Med 2017;52(3):362–372. Published by Elsevier Inc. on behalf of American Journal of Preventive
Medicine
INTRODUCTION
Herpes zoster, or shingles, is caused by reactiva-tion of the varicella zoster virus. The risk ofshingles increases with age and is approxi-
mately three times higher among adults agedZ65 years
compared with those agedo65 years.1–4 More than half
of all people diagnosed with shingles each year are aged
Z50 years.4 In the U.S., more than 99% of adults have
serologic evidence of varicella zoster virus infection and
are susceptible to shingles,5 with an estimated individual
lifetime risk of approximately 30%.4 Ten to 30 percent of
people experiencing shingles develop postherpetic neu-
ralgia (PHN), a debilitating neuropathic pain syndrome
that can last months or even years and is often refractory
to treatment, with the risk of PHN increasing with
age.3,4,6 Approximately 1 million new cases of shingles
are diagnosed annually.4–11 The incidence rate of shingles
ranges between three and five per 1,000 person-years in
prior studies in the U.S. and other countries, depending
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on the studied population and immunocompetency of
subjects.4–11 Shingles results in an estimated $566 million
in total healthcare costs.12 Additionally, shingles causes
indirect cost with an average loss exceeding 129 hours of
work per episode.7,13 Much of the burden of shingles and
PHN is, however, borne by patients as reduced quality of
life because of associated pain and suffering.3,6
The zoster vaccine, Zostavaxs, was licensed in 2006 by
the U.S. Food and Drug Administration for prevention of
shingles, as well as prevention and treatment of PHN.
The Advisory Committee on Immunization Practices
(ACIP) recommended routine vaccination of all people
aged Z60 years with one dose of zoster vaccine in
October 2006; these recommendations were published in
May 2008.6,14 Cost effectiveness of Zostavax varies
depending on patients’ age and is more cost effective
for patients aged 60–70 years but is not as cost effective
for patients aged480 years.15,16
This study used data from the 2014 Behavioral Risk
Factor Surveillance System (BRFSS) to assess recent
national and state-specific shingles vaccination coverage
and identify factors independently associated with vac-
cination among adults aged Z60 years in the U.S. Such
information may help identify which strategies can help
improve vaccination coverage among adult populations.
METHODS
The 2014 BRFSS data were analyzed in 2015. BRFSS is a continuous,
population-based telephone survey coordinated by state health
departments in collaboration with the Centers for Disease Control
and Prevention (CDC). BRFSS collects information from non-
institutionalized adults aged Z18 years. BRFSS is conducted
monthly in all 50 states and the District of Columbia (DC). The
objective of BRFSS is to collect uniform, state-specific data on self-
reported preventive health practices and risk behaviors that are
linked to chronic diseases, injuries, and preventable infectious
diseases. Individuals are selected randomly using a multistage
cluster design. Data are weighted by age, sex, and in some states,
race/ethnicity, to reflect each area’s estimated adult population.17
Beginning in 2011, surveys included landline and cellular telephone
households and used a new method for weighting.18
To determine shingles vaccination status in all states, a question
on shingles vaccination was added to the 2014 BRFSS core
questionnaire as part of a 3-year rotation with questions to assess
tetanus diphtheria and tetanus, diphtheria, and acellular pertussis
vaccination coverage (2013) and in place of influenza vaccination
(2015). Respondents were asked, Have you ever had the shingles or
zoster vaccine? Respondents who answered yes were considered
vaccinated. For 2014 BRFSS, the median American Association of
Public Opinion Research (RR4) landline, cellular phone, and
combined response rates were 48.7% (range, 26.7%–61.6%);
40.5% (range, 22.2%–60.0%); and 25.1% (range, 25.1%–60.1%),
respectively.19
SUDAAN, version 11.0.1, was used to calculate point estimates
and 95% CIs.20 All analyses were weighted to reflect the age, sex,
and race/ethnicity of the U.S. non-institutionalized civilian pop-
ulation. All tests were two-tailed with the significance level set at
αo0.05. State-specific shingles vaccination coverage was also
evaluated. Multivariable logistic regression models were conducted
(all variables selected were included in the model) and predictive
marginal models20 were used to generate adjusted prevalence and
adjusted prevalence differences and to identify variables independ-
ently associated with shingles vaccination among adults aged
Z60 years.
RESULTS
A total of 208,505 adults aged Z60 years were included
in the 2014 BRFSS. Of those, 1.7% (3,486) who answered
don’t know or declined to the question were excluded
from the assessment of shingles vaccination. Demo-
graphic characteristics of the study population are
provided in Table 1. The majority of participants were
aged 60–74 years (70.0%); female (54.8%); white (77.5%);
married or a member of an unmarried couple (59.1%);
had some college (or technical school) education or
higher (54.5%); were not in workforce (72.9%); had
household income o$50,000 (61.5%); living in South
or West (59.7%); perceived their health status as being
excellent/very good or good (74.7%); had medical insur-
ance (96.1%); had a personal healthcare provider
(92.9%); had a routine checkup last year (85.6%); and
did not report that cost prevented them from seeing a
doctor during the past 12 months (93.0%).
In the univariate analysis, shingles vaccination cover-
age was 31.8% (95% CI¼31.4%, 32.2%) among adults
aged Z60 years. Shingles vaccination coverage was
significantly higher among adults aged 65–74 years
(35.9%); 75–79 years (37.7%); and Z80 years (34.3%)
compared with adults aged 60–64 years (22.0%)
(Table 2). Coverage was 5.9% among adults aged 50–59
years (data not shown). Shingles vaccination coverage
among adults aged Z60 years was significantly lower
among non-Hispanic blacks (16.0%); Hispanics (16.7%);
and American Indians and Alaska Natives (27.2%)
compared with non-Hispanic whites (35.4%), but was
not significantly lower for Asians (30.2%) compared with
non-Hispanic whites. Shingles vaccination coverage was
significantly higher among adults who were female,
reported having higher education, reported higher
income, were not in workforce, were living in the
Midwest or West of the U.S., perceived their health
status as being excellent/very good or good, reported
having medical insurance, reported having a personal
healthcare provider, reported having a routine checkup
in the previous year, and did not report that cost
prevented them from seeing a doctor (Table 2). Shingles
vaccination coverage was significantly lower among those
who reported being widowed, divorced, separated, or
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never married; being unemployed; or living in the South
of the U.S. (Table 2).
In multivariable analysis, characteristics independently
associated with an increased likelihood of shingles vacci-
nation among adults agedZ60 years were older age; being
female; higher education; not being in the workforce,
household incomeZ$20,000; living in the Midwest, West,
or South of the U.S.; perceived health status being
excellent/very good, good, or fair; having health insurance;
having a personal healthcare provider; having a routine
checkup in the previous year; and not reporting that cost
prevented them from seeing a doctor during the past 12
months (Table 3). African American and Asian race and
Hispanic ethnicity were independently associated with a
decreased likelihood of shingles vaccination (Table 3).
Among all 50 states and DC, shingles vaccination
coverage among adults aged Z60 years varied widely,
ranging from 17.8% in Mississippi to 46.6% in Vermont,
with a median of 33.3%. Overall coverage ranged from
25.1% in DHHS Region 2 to 43.2% in Region 10. Shingles
vaccination coverage among adults aged Z60 years was
o25% in four states (Mississippi, New Jersey, Louisiana,
and Alabama) and 440% in nine states (Vermont,
Oregon, Washington, Minnesota, North Dakota, Colo-
rado, Maine, South Dakota, and Nebraska) (Table 4).
Shingles vaccination coverage among non-Hispanic
white adults aged Z60 years ranged from 22.3% in
Mississippi to 52.8% in DC, with a median of 35.7%.
Coverage waso25% in two states (Mississippi and New
Jersey);445% in four states (DC, Vermont, Washington,
Minnesota); and 430% in 34 states (Table 4). Shingles
vaccination coverage among non-white adults agedZ60
years ranged from 6.3% in Mississippi to 45.6% in
Oregon, with a median of 20.3%. Coverage among
non-white adults aged Z60 years was o15% in nine
states (Illinois, Missouri, Georgia, Florida, New York,
Table 1. Sample Characteristics Among Adults Aged Z60
years, U.S., BRFSS 2014
All adults
Characteristic
Sample
(n)
Weighted
%
Total 208,505 100.0
Age (years)
60–64 51,850 29.3
65–74 89,423 40.7
75–79 28,837 13.9
Z80 38,395 16.1
Sex
Male 81,386 45.2
Female 127,119 54.8
Race/ethnicity
White, non-Hispanic 176,277 77.5
Black, non-Hispanic 13,506 9.7
Hispanic 6,717 7.9
Asian, non-Hispanic 2,135 2.7
American Indian/Alaska Native, non-
Hispanic
2,320 0.8
Other 4,025 1.4
Marital status
Married or unmarried couple 108,322 59.1
Divorced, widowed, or separated 87,366 36.2
Never married 11,408 4.7
Education level
Less than high school 17,757 15.2
High school graduate 63,552 30.3
Some college or
technical school
54,998 29.7
College graduate or higher education 70,688 24.8
Employment
Employed 50,179 24.5
Unemployed 4,099 2.6
Not in workforce 152,259 72.9
Income ($)
o20,000 33,848 21.1
20,000–49,999 71,840 40.4
50,000–74,999 26,891 15.5
Z75,000 37,788 23.0
Region
Northeast 37,378 18.5
Midwest 57,096 21.8
South 64,449 37.6
West 49,582 22.1
Perceived health
Excellent or very good 92,772 42.2
Good 67,071 32.5
Fair 33,259 17.5
Poor 14,431 7.8
Have medical insurance
Yes 202,433 96.1
No 5,552 3.9
(continued on next page)(continued)
Table 1. (continued)
All adults
Characteristic
Sample
(n)
Weighted
%
Have personal healthcare provider
Yes 193,696 92.9
No 13,979 7.1
Time since last routine checkup
o1 year 173,335 85.6
Z1 year 31,257 14.4
Unable to see doctor due to cost
Yes 11,878 7.0
No 196,036 93
BRFSS, Behavioral Risk Factor Surveillance System.
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Table 2. Shingles Vaccination Coverage Among Adults Aged Z60 Years by Selected Demographic and Access-to-Care
Characteristics—U.S., BRFSS 2014
Characteristic
Shingles vaccination
coverage, % (95% CI)
Difference,a %
(95% CI)
Total 31.8 (31.4, 32.2) NA
Age (years)
60–64b 22.0 (21.3, 22.7) ref
65–74 35.9 (35.3, 36.6)* 14.0 (13.0, 14.9)
75–79 37.7 (36.6, 38.9)* 15.8 (14.4, 17.1)
Z80 34.3 (33.3, 35.2)* 12.3 (11.1, 13.5)
Sex
Maleb 30.6 (29.9, 31.2) ref
Female 32.9 (32.3, 33.4)* 2.3 (1.5, 3.1)
Race/ethnicity
White, non-Hispanicb 35.4 (35.0, 35.8) ref
Black, non-Hispanic 16.0 (14.7, 17.4)* –19.4 (–20.8, –18.0)
Hispanic 16.7 (14.9, 18.6)* –18.7 (–20.6, –16.8)
Asian, non-Hispanic 30.2 (25.2, 35.8) –5.1 (–10.4, 0.2)
American Indian/Alaska Native, non-Hispanic 27.2 (23.6, 31.1)* –8.2 (–12.0, –4.4)
Other 27.2 (24.2, 30.6)* –8.1 (–11.3, –4.9)
Marital status
Married or unmarried coupleb 34.3 (33.7, 34.8) ref
Divorced, widowed, or separated 28.7 (28.1, 29.4)* –5.6 (–6.4, –4.7)
Never married 25.0 (23.3, 26.7)* –9.3 (–11.1, –7.5)
Education level
Less than high schoolb 17.9 (16.8, 19.0) ref
High school graduate 28.5 (27.8, 29.2)* 10.6 (9.3, 11.9)
Some college or technical school 32.7 (31.9, 33.5)* 14.8 (13.5, 16.2)
College graduate or higher education 43.0 (42.3, 43.7)* 25.1 (23.8, 26.4)
Employment
Employedb 26.8 (26.1, 27.6) ref
Unemployed 17.8 (15.6, 20.3)* –9.0 (–11.5, –6.5)
Not in workforce 34.0 (33.5, 34.5)* 7.2 (6.3, 8.1)
Income ($)
o20,000b 18.4 (17.5, 19.3) ref
20,000–49,999 30.1 (29.5, 30.8)* 11.8 (10.7, 12.8)
50,000–74,999 38.0 (36.9, 39.2)* 19.7 (18.2, 21.1)
Z75,000 41.9 (40.9, 42.9)* 23.5 (22.2, 24.8)
Region
Northeastb 30.3 (29.4, 31.2) ref
Midwest 33.2 (32.5, 33.9)* 2.9 (1.8, 4.1)
South 28.7 (28.1, 29.3)* –1.5 (–2.6, –0.5)
West 37.4 (36.3, 38.6)* 7.1 (5.7, 8.6)
Perceived health
Excellent or very good 37.0 (36.4, 37.6)* 17.2 (15.8, 18.6)
Good 31.8 (31.1, 32.5)* 12.0 (10.5, 13.4)
Fair 24.6 (23.7, 25.6)* 4.8 (3.2, 6.4)
Poorb 19.8 (18.6, 21.1) ref
Have medical insurance
Yes 32.7 (32.3, 33.1)* 23.3 (21.9, 24.8)
Nob 9.4 (8.1, 10.9) ref
(continued on next page)
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South Carolina, Alabama, Louisiana, and Mississippi)
and 430% in eight states (Oregon, Hawaii, North
Dakota, New Hampshire, Washington, Colorado, Min-
nesota, and Wyoming) (Table 4). For all states, shingles
coverage was significantly higher among non-Hispanic
whites compared with non-white races except for Ore-
gon, with coverage differences ranging from –33.2% in
DC to 0.9% in Oregon and a median of –16.0%.
DISCUSSION
Shingles vaccination coverage exceeded 30% in 34 states,
indicating that a majority of states reached the Healthy
People 2020 target of 30% coverage among adults aged
Z60 years,21 although a large majority of Americans
have not received the shingles vaccine. Although BRFSS
is a population-based survey designed to produce repre-
sentative state-level assessments, data are routinely
aggregated for national estimation of certain behavior
and health outcomes. Comparing the shingles vaccina-
tion coverage estimate in this study derived by aggregat-
ing 2014 BRFSS state-level data (31.8%) to the estimate
(27.9%) from the nationally representative 2014 National
Health Interview Survey22 revealed a 3.9–percentage
point difference. The difference in coverage estimates
between these two surveys might be due to differences in
survey design and administration; operations (in-person
survey for the National Health Interview Survey,
and telephone survey for BRFSS), and weighting
procedures.18,19,22,23
A 2007 U.S. study showed that soon after shingles
vaccine was licensed and recommended for people aged
Z60 years in 2006, vaccination coverage in this target
population was 1.9%.24 Shingles vaccination coverage has
steadily increased since vaccine licensure.22,24,25 Shingles
vaccination coverage among adults aged Z60 years
reached 31.8% in 2014, which was 8 years after the
recommendation. Shingles vaccination coverage could be
compared to pneumococcal polysaccharide vaccination,
another vaccine that was recommended to senior adults
in 1983. Pneumococcal vaccine coverage increased to
21%–24% among adults aged Z65 years by 1991–1992
(8 years after recommendation); coverage then further
increased to 58%–69% in 2014.22,26,27 To increase vacci-
nation coverage among senior adults, healthcare pro-
viders are encouraged to include vaccination status
assessment, recommendation and offer of vaccination,
or referral if vaccines that are needed are not available, as
a routine in their practices.28
Several factors might have contributed to slower
shingles vaccination uptake. First, shortages of herpes
zoster vaccine and a resulting lack of vaccine promotion
likely contributed to low uptake during the first years
after vaccine licensure. Although these shortages have
been resolved, other barriers persist, particularly high
vaccine cost for providers and challenges to stocking the
vaccine (stringent storage and handling requirements)
and receiving reimbursement for vaccination serv-
ices.22,25,29 Second, coverage for shingles vaccine under
Medicare Part D results in billing challenges for pro-
viders (except pharmacists) and out-of-pocket expenses
for some Medicare Part D beneficiaries (high co-pays;
median, approximately $70–$80), and additionally, not
every Medicare recipient has elected to participate in Part
D.22,29 Third, physicians were not strongly promoting
shingles vaccination to their patients. One study showed
that only 41% of providers strongly recommended
shingles vaccine to their patients compared with more
than 90% who strongly recommended influenza and
pneumococcal vaccination.29 Fourth, awareness of
Table 2. Shingles Vaccination Coverage Among Adults Aged Z60 Years by Selected Demographic and Access-to-Care
Characteristics—U.S., BRFSS 2014 (continued)
Characteristic
Shingles vaccination
coverage, % (95% CI)
Difference,a %
(95% CI)
Have personal health care provider
Yes 33.1 (32.7, 33.5)* 17.4 (15.9, 18.8)
Nob 15.7 (14.4, 17.1) ref
Time since last routine checkup
o1 year 34.0 (33.5, 34.4)* 13.6 (12.6, 14.6)
Z1 yearb 20.4 (19.5, 21.3) ref
Unable to see doctor due to cost
Yesb 15.9 (14.6, 17.3) ref
No 33.0 (32.6, 33.5)* 17.1 (15.7, 18.5)
Note: Boldface indicates statistical significance (*po0.05 by t test comparing against reference group).
aPercentage point difference compared to the reference group.
bReference level.
BRFSS, Behavioral Risk Factor Surveillance System.
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Table 3. Multivariable Logistic Regression Analysis of Persons Aged Z60 Years Who Reported Shingles Vaccination, by
Selected Demographic and Access-to-Care Characteristics, U.S., BRFSS 2014
Characteristic
Adjusted shingles vaccination coverage, %
(95% CI)
Adjusted prevalence difference (PD), PD
(95% CI)
Age (years)
60–64a 24.1 (23.2, 24.9) ref
65–74 35.0 (34.3, 35.7) 10.9 (9.8, 12.0)*
75–79 37.7 (36.4, 39.0) 13.7 (12.1, 15.2)*
Z80 34.9 (33.8, 36.1) 10.9 (9.4, 12.4)*
Sex
Malea 30.4 (29.7, 31.0) ref
Female 33.7 (33.1, 34.3) 3.4 (2.5, 4.3)*
Race/ethnicity
White, non-Hispanica 34.0 (33.6, 34.5) ref
Black, non-Hispanic 20.1 (18.3, 21.9) –13.9 (–15.8, –12.1)*
Hispanic 25.2 (22.6, 27.8) –8.9 (–11.5, –6.2)*
Asian, non-Hispanic 27.3 (22.5, 32.0) –6.8 (–11.5, –2.0)*
American Indian/Alaska Native, non-
Hispanic
34.0 (29.4, 38.6) –0.1 (–4.7, 4.5)
Other 30.8 (27.0, 34.7) –3.2 (–7.1, 0.7)
Marital status
Married or unmarried couplea 32.3 (31.7, 32.9) ref
Divorced, widowed, or separated 31.9 (31.1, 32.6) –0.5 (–1.5, 0.6)
Never married 31.7 (29.5, 33.9) –0.6 (–2.9, 1.7)
Education level
Less than high schoola 25.5 (23.8, 27.2) ref
High school graduate 29.1 (28.3, 29.9) 3.5 (1.7, 5.4)*
Some college or technical school 31.9 (31.1, 32.7) 6.3 (4.5, 8.2)*
College graduate or higher education 38.2 (37.4, 39.0) 12.6 (10.7, 14.6)*
Employment
Employeda 26.6 (25.7, 27.4) ref
Unemployed 26.9 (23.6, 30.3) 0.4 (–3.1, 3.8)
Not in workforce 34.3 (33.8, 34.9) 7.8 (6.7, 8.8)*
Income ($)
o20,000a 23.7 (22.6, 24.9) ref
20,000–49,999 30.0 (29.3, 30.7) 6.3 (5.0, 7.6)*
50,000–74,999 35.9 (34.8, 37.0) 12.2 (10.5, 13.9)*
Z75,000 39.1 (38.0, 40.2) 15.4 (13.6, 17.2)*
Region
Northeasta 29.1 (28.2, 30.0) ref
Midwest 32.7 (31.9, 33.4) 3.6 (2.4, 4.8)*
South 30.4 (29.7, 31.1) 1.3 (0.2, 2.5)*
West 37.2 (36.1, 38.4) 8.1 (6.7, 9.6)*
Perceived health
Excellent or very good 34.3 (33.6, 35.0) 9.0 (7.1, 10.9)*
Good 32.2 (31.4, 33.0) 6.9 (5.0, 8.8)*
Fair 28.4 (27.2, 29.5) 3.1 (1.0, 5.1)*
Poora 25.3 (23.6, 27.0) ref
Have medical insurance
Yes 32.3 (31.8, 32.8) 8.9 (5.6, 12.3)*
Noa 23.4 (20.1, 26.7) ref
Have personal healthcare provider
Yes 32.5 (32.0, 33.0) 7.3 (5.0, 9.6)*
Noa 25.2 (23.0, 27.5) ref
(continued on next page)
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shingles vaccine among patients was low,24 particularly if
providers were not aggressively promoting the shingles
vaccination. One study reported that in 2008, 2 years
after vaccine licensure, only 27% of adults aged Z60
years were aware of the shingles vaccine.24 In 2015, 73.4%
of the target population reported awareness of the
shingles vaccine (CDC, Immunization Services Division,
unpublished data), indicating that by the end of 2014,
8 years after shingles vaccine was recommended, the
large majority of adults were aware of the shingles
vaccine but approximately one fourth of adults aged
Z60 years did not know about the vaccine despite a
major sustained direct-to-consumer TV advertising
campaign sponsored by the manufacturer. Compared
with shingles vaccine, in 2015, a total of 86.6% of adults
Z65 years reported awareness of the pneumococcal
vaccine. Finally, most people without medical insurance
were confronted with substantial financial barriers, as the
high retail price of shingles vaccine would need to be paid
out of pocket. For those with commercial insurance, out-
of-pocket costs are less clear. For adults agedZ60 years
with non-grandfathered private health insurance plans,
shingles vaccine is available with no out-of-pocket costs
because of provisions of the Affordable Care Act.22,29
Strategies are needed to mitigate financial barriers,
improve awareness, and increase provider recommenda-
tion of the vaccine.
Because shingles vaccination information was newly
added to the 2014 BRFSS core questionnaire, this is the
first study to assess state-specific shingles vaccination
coverage among adult populations across the entire U.S.
The shingles vaccination question will be added to the
2017 BRFSS core questionnaire as part of its 3-year
rotation with two other questions. Results from this study
provide a baseline for state-level shingles coverage in the
U.S. Substantial differences in coverage among states
were observed for shingles vaccination. Variation in state
coverage could be due to differing medical care delivery
infrastructure, population composition, socioeconomic
factors, state laws, effectiveness of state and local
immunization programs among states, and other fac-
tors.23,30–33 Wide variation in vaccination coverage
among states has also been observed for influenza and
pneumococcal vaccination among older adults in a
similar pattern as shingles vaccination,27,34 possibly
because of comparable factors. State-specific influenza
vaccination coverage in the 2014–2015 season among
adults agedZ65 years ranged from 57.2% to 76.8%, and
pneumococcal vaccination coverage in 2014 among
adults aged Z65 years ranged from 60.5% to
76.1%.27,34 Because there is a wide variation in vacci-
nation of elderly adults across states, future research on
state-specific factors associated with vaccination could
prompt actions, policies, and programs in other states to
increase vaccination uptake. State immunization pro-
grams are encouraged to engage providers and other
stakeholders to implement interventions shown to be
effective in increasing vaccination among adults.35
Of note, this analysis showed that shingles vaccination
coverage was 5.9% among adults aged 50–59 years for
whom the vaccine is licensed by the U.S. Food and Drug
Administration but not recommended by ACIP.36 The
lower coverage among adults aged 50–59 years compared
with other age groups may be partially due to lack of
official recommendation of the vaccine by ACIP. Addi-
tional information is needed on long-term protection
afforded by herpes zoster vaccine in this age group and
cost effectiveness of vaccination at younger versus older
ages to assist future decisions on recommending shingles
vaccination in younger groups.
Racial and ethnic disparities in vaccination rates have
been reported for adult vaccines, including those for
influenza, pneumococcal, tetanus, shingles, human pap-
illomavirus, and hepatitis B vaccines.37–40 The present
findings are consistent with those reported previously
from a nationally representative survey.40 In this study,
Table 3. Multivariable Logistic Regression Analysis of Persons Aged Z60 Years Who Reported Shingles Vaccination, by
Selected Demographic and Access-to-Care Characteristics, U.S., BRFSS 2014 (continued)
Characteristic
Adjusted shingles vaccination coverage, %
(95% CI)
Adjusted prevalence difference (PD), PD
(95% CI)
Time since last routine checkup
o1 year 33.6 (33.1, 34.1) 10.7 (9.5, 11.9)*
Z1 yeara 22.9 (21.8, 24.0) ref
Unable to see doctor due to cost
Yesa 26.7 (24.6, 28.7) ref
No 32.4 (31.9, 32.9) 5.8 (3.7, 7.8)*
Note: Boldface indicates statistical significance (po0.05 by t test comparing against reference group).
aReference level.
BRFSS, Behavioral Risk Factor Surveillance System.
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Table 4. State-Specific Shingles Vaccination Coverage Among Adults AgedZ60 Years by DHHS Regions, U.S., BRFSS 2014
DHHS region/state Sample size
Total, %
(95% CI)
Non-Hispanic
white, % (95% CI)
Persons of all other
racial/ethnic
groups, % (95% CI)
Difference,a %
(95% CI)
Region 1 22,347 37.6 (36.6, 38.6) 39.6 (38.6, 40.6) 21.1 (18.0, 24.4) –18.5 (–21.9, –15.2)*
Connecticut 3,265 32.0 (30.0, 34.2) 35.1 (32.8, 37.4) 17.0 (12.5, 22.7) –18.0 (–23.6, –12.5)*
Maine 4,258 42.1 (40.3, 43.9) 42.5 (40.6, 44.4) 26.3 (17.5, 37.5) –16.2 (–26.5, –5.9)*
Massachusetts 6,823 38.6 (36.9, 40.3) 40.8 (39.0, 42.6) 22.8 (18.1, 28.1) –18.0 (–23.3, –12.7)*
New Hampshire 2,773 39.3 (37.0, 41.7) 39.3 (36.9, 41.7) 36.3 (24.0, 50.7) –3.0 (–16.8, 10.9)
Rhode Island 2,789 34.7 (32.6, 36.9) 36.5 (34.3, 38.8) 19.2 (14.0, 25.8) –17.3 (–23.7, –11.0)*
Vermont 2,439 46.6 (44.3, 48.8) 47.7 (45.3, 50.0) 24.9 (15.7, 37.3) –22.7 (–33.9, –11.6)*
Region 2 7,490 25.1 (23.6, 26.7) 29.6 (27.9, 31.4) 13.6 (10.9, 17.0) –16.0 (–19.5, –12.5)*
New Jersey 4,960 22.5 (20.8, 24.3) 24.9 (23.0, 26.9) 15.9 (12.5, 20.0) –9.0 (–13.2, –4.8)*
New York 2,530 26.4 (24.3, 28.5) 31.9 (29.5, 34.4) 12.7 (9.2, 17.3) –19.2 (–23.9, –14.5)*
Region 3 21,048 32.8 (31.9, 33.8) 35.6 (34.6, 36.7) 20.4 (18.2, 22.7) –15.3 (–17.8, –12.7)*
Delaware 1,980 30.4 (28.0, 33.0) 33.3 (30.6, 36.2) 17.9 (13.3, 23.7) –15.4 (–21.3, –9.5)*
District of Columbia 1,821 32.6 (29.8, 35.6) 52.8 (48.3, 57.3) 19.6 (16.2, 23.6) –33.2 (–39.1, –27.3)*
Maryland 5,817 34.4 (32.4, 36.5) 38.6 (36.4, 40.8) 25.5 (21.0, 30.6) –13.1 (–18.4, –7.8)*
Pennsylvania 4,921 32.3 (30.7, 34.0) 34.2 (32.5, 36.0) 17.0 (13.2, 21.7) –17.2 (–21.8, –12.6)*
Virginia 3,803 34.7 (32.8, 36.7) 39.3 (37.2, 41.6) 19.0 (15.6, 23.0) –20.3 (–24.6, –16.0)*
West Virginia 2,706 26.6 (24.8, 28.5) 27.4 (25.6, 29.4) 15.2 (9.3, 23.9) –12.2 (–19.7, –4.8)*
Region 4 28,940 27.9 (27.1, 28.6) 32.2 (31.4, 33.1) 12.6 (11.2, 14.2) –19.6 (–21.3, –17.9)*
Alabama 3,964 23.7 (22.1, 25.4) 27.4 (25.4, 29.4) 11.7 (9.2, 14.7) –15.7 (–19.1, –12.3)*
Florida 4,873 28.5 (26.9, 30.0) 33.6 (31.9, 35.3) 12.9 (10.1, 16.3) –20.7 (–24.2, –17.2)*
Georgia 2,715 27.2 (25.2, 29.3) 32.8 (30.4, 35.3) 13.0 (10.1, 16.6) –19.8 (–23.9, –15.8)*
Kentucky 4,981 29.8 (27.8, 31.8) 30.8 (28.8, 32.9) 17.9 (12.1, 25.6) –12.9 (–20.0, –5.9)*
Mississippi 1,993 17.8 (15.8, 20.0) 22.3 (19.7, 25.1) 6.3 (4.3, 9.2) –16.0 (–19.6, –12.4)*
North Carolina 2,950 32.2 (30.3, 34.1) 36.2 (34.0, 38.4) 16.3 (13.0, 20.3) –19.9 (–24.1, –15.6)*
South Carolina 5,035 26.4 (24.9, 28.0) 30.7 (28.9, 32.5) 12.2 (9.8, 15.1) –18.5 (–21.7, –15.3)*
Tennessee 2,429 27.8 (25.6, 30.1) 31.1 (28.7, 33.7) —b –23.3 (–28.8, –17.8)*
Region 5 24,927 32.7 (31.9, 33.6) 35.1 (34.1, 36.0) 18.2 (15.7, 20.9) –16.9 (–19.7, –14.1)*
Illinois 2,064 28.1 (25.8, 30.6) 32.2 (29.6, 34.9) 14.1 (9.9, 19.8) –18.0 (–23.7, –12.4)*
Indiana 5,157 29.4 (27.9, 30.9) 31.1 (29.5, 32.7) 15.1 (11.0, 20.5) –16.0 (–21.0, –11.0)*
Michigan 3,725 33.3 (31.6, 35.1) 35.7 (33.8, 37.6) 20.3 (15.9, 25.7) –15.4 (–20.6, –10.1)*
Minnesota 5,953 44.2 (42.7, 45.7) 45.2 (43.7, 46.7) 31.1 (24.1, 39.0) –14.1 (–21.7, –6.5)*
Ohio 5,099 31.4 (29.6, 33.3) 33.0 (31.0, 35.0) 21.3 (16.4, 27.2) –11.7 (–17.4, –5.9)*
Wisconsin 2,929 37.1 (34.6, 39.6) 38.0 (35.5, 40.5) 20.4 (12.8, 30.9) –17.6 (–27.0, –8.2)*
Region 6 19,296 28.7 (27.4, 30.0) 33.0 (31.6, 34.5) 18.7 (16.1, 21.6) –14.3 (–17.4, –11.2)*
Arkansas 2,744 27.8 (25.7, 30.1) 29.6 (27.3, 32.1) 17.2 (11.6, 24.6) –12.5 (–19.4, –5.6)*
Louisiana 2,672 22.5 (20.7, 24.4) 27.1 (24.8, 29.4) 11.7 (9.2, 14.7) –15.4 (–18.9, –11.8)*
New Mexico 3,705 37.5 (35.3, 39.8) 44.5 (41.7, 47.3) 27.1 (23.6, 31.0) –17.3 (–22.0, –12.7)*
Oklahoma 3,823 28.4 (26.8, 30.1) 29.4 (27.7, 31.3) 23.1 (19.3, 27.4) –6.3 (–10.7, –1.9)*
Texas 6,352 29.3 (27.3, 31.4) 34.9 (32.5, 37.3) 18.7 (15.1, 22.8) –16.2 (–20.8, –11.7)*
Region 7 22,653 34.1 (33.0, 35.2) 36.0 (34.9, 37.1) 15.5 (12.9, 18.5) –20.5 (–23.5, –17.5)*
Iowa 3,618 39.4 (37.6, 41.3) 40.3 (38.4, 42.2) 16.6 (9.5, 27.4) –23.7 (–32.7, –14.7)*
Kansas 5,676 33.6 (32.3, 35.0) 35.5 (34.1, 36.9) 16.6 (13.1, 20.9) –18.8 (–23.0, –14.7)*
Missouri 3,417 29.6 (27.5, 31.7) 31.7 (29.5, 34.0) 13.8 (10.2, 18.5) –17.9 (–22.6, –13.2)*
Nebraska 9,942 41.0 (39.5, 42.4) 42.7 (41.2, 44.1) 21.1 (15.9, 27.4) –21.5 (–27.5, –15.6)*
Region 8 23,652 40.0 (39.1, 40.9) 41.3 (40.4, 42.3) 30.3 (26.9, 34.0) –11.0 (–14.7, –7.3)*
Colorado 5,236 42.4 (40.8, 44.0) 44.7 (43.0, 46.4) 31.7 (27.2, 36.7) –13.0 (–18.1, –7.9)*
Montana 3,632 36.3 (34.1, 38.5) 37.3 (35.0, 39.6) 22.0 (16.4, 28.8) –15.3 (–21.9, –8.7)*
North Dakota 3,561 42.6 (40.3, 44.8) 43.0 (40.8, 45.3) 36.4 (19.5, 57.4) –6.6 (–26.6, 13.3)
South Dakota 3,204 41.1 (38.3, 44.1) 42.0 (39.1, 45.0) 28.2 (16.3, 44.2) –13.8 (–28.4, 0.7)
(continued on next page)
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racial and ethnic disparities in shingles vaccination
coverage also were observed in most states. In addition,
although shingles vaccination is publically funded in the
United Kingdom with an aggressive vaccination pro-
gram, disparities in shingles vaccine uptake between
white and racial and ethnic minority populations also
exist.41 These disparities may reflect differences in
general quality of care, community differences in atti-
tudes toward vaccination and preventive care in general,
differences in concerns about vaccination, including
safety, or differences in doctor–patient interactions.37–40
To improve coverage and eliminate disparities in adult
vaccination, greater implementation of evidence-based
interventions are needed, including the use of reminder/
recall systems, standing orders for vaccination, regular
assessments of vaccination coverage levels among pro-
vider practices, vaccination registries, and improving
public and provider awareness of the importance of
vaccinations for adults.35,37–42
Women were more likely to receive shingles vaccina-
tion than men. This may partly be because women are
more aware of shingles and shingles vaccine or generally
see healthcare providers and use preventive service more
frequently than men.24,43,44 Educational levels were
also independently positively associated with shingles
vaccination. People with less education may experience
more barriers to receiving care perhaps because of lack of
knowledge regarding preventive services45,46 in general
or regarding shingles vaccine specifically.24,29
Additionally, having health insurance, a personal health-
care provider, and a routine checkup in the previous year
were independently associated with higher shingles
vaccination coverage. These findings are consistent with
previous reports.37–39,47–50
Limitations
The findings in this report are subject to at least two
limitations. First, vaccination coverage was self-reported
and therefore might be subject to recall bias. However,
adult self-reported vaccination status for shingles and
other vaccines has been shown to be sensitive and
specific.51 In addition, the authors were not able to
determine age-specific vaccine uptake, as BRFSS
respondents were asked whether they had ever received
the vaccine, and time of vaccination was not collected.
Thus, for instance, a person aged 80 years who reported
receipt of shingles vaccine might have been vaccinated
soon after vaccine licensure in 2006, when they were aged
72 years.
CONCLUSIONS
Use of zoster vaccine can significantly reduce morbidity
caused by shingles among adults agedZ60 years. CDC is
actively monitoring post-marketing data on duration of
vaccine protection in adults vaccinated at ageZ60 years.
As additional data become available, ACIP will re-
evaluate the need for a booster dose to maintain
Table 4. State-Specific Shingles Vaccination Coverage Among Adults AgedZ60 Years by DHHS Regions, U.S., BRFSS 2014
(continued)
DHHS region/state Sample size
Total, %
(95% CI)
Non-Hispanic
white, % (95% CI)
Persons of all other
racial/ethnic
groups, % (95% CI)
Difference,a %
(95% CI)
Utah 4,635 37.4 (35.7, 39.1) 38.5 (36.8, 40.3) 27.7 (21.1, 35.5) –10.8 (–18.3, –3.4)*
Wyoming 3,384 32.7 (30.6, 34.9) 32.7 (30.6, 34.8) 30.1 (20.5, 42.0) –2.5 (–13.6, 8.6)
Region 9 14,421 34.9 (33.1, 36.7) 40.1 (38.1, 42.0) 25.9 (22.6, 29.6) –14.1 (–18.2, –10.1)*
Arizona 7,639 33.4 (32.0, 34.9) 36.9 (35.3, 38.4) 20.5 (16.7, 24.8) –16.4 (–20.7, –12.1)*
California 2,406 35.5 (33.1, 38.0) 42.0 (39.2, 44.8) 25.4 (21.2, 30.1) –16.6 (–21.9, –11.3)*
Hawaii 2,776 38.8 (36.2, 41.4) 40.7 (36.7, 44.7) 38.2 (34.9, 41.5) –2.5 (–7.7, 2.7)
Nevada 1,600 30.1 (26.6, 33.9) 31.9 (28.6, 35.5) 26.1 (17.6, 37.0) –5.8 (–16.2, 4.6)
Region 10 10,897 43.2 (41.9, 44.4) 44.2 (42.9, 45.4) 36.5 (31.9, 41.3) –7.7 (–12.6, –2.8)*
Alaska 1,397 33.4 (30.2, 36.9) 35.3 (31.9, 38.9) 27.3 (19.5, 36.7) –8.0 (–17.4, 1.3)
Idaho 2,436 37.0 (34.4, 39.7) 37.6 (35.0, 40.3) 29.7 (17.5, 45.7) –7.9 (–22.6, 6.7)
Oregon 2,455 44.6 (42.3, 47.0) 44.7 (42.4, 47.1) 45.6 (36.0, 55.6) 0.9 (–9.3, 11.1)
Washington 4,609 44.4 (42.6, 46.2) 46.0 (44.1, 47.8) 35.1 (29.1, 41.6) –10.8 (–17.4, –4.3)*
Median 33.3 35.7 20.3 –16.0
Range 17.8, 46.6 22.3, 52.8 6.3, 45.6 –33.2, 0.9
Note: Boldface indicates statistical significance (po0.05 by t test comparing non-Hispanic white with persons of all other racial/ethnic groups).
aDifference between non-Hispanic white and persons of all other racial/ethnic groups.
bEstimate may not be reliable because of relative SE 430%.
BRFSS, Behavioral Risk Factor Surveillance System; DHHS, Department of Health and Human Services.
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protection against herpes zoster and its complications.36
If all eligible adults aged Z60 years are vaccinated in
accordance with ACIP recommendations, the vaccine
could prevent a quarter of a million cases of shingles
annually.52,53 However, this study found that 8 years after
shingles vaccine became available, vaccination coverage
was only 31.8%, and coverage varied by states. Increased
state and national efforts using comprehensive strategies
shown to be effective are needed to improve shingles
vaccination coverage levels. Financial barriers to providers
(vaccine purchase and compensation) and patients (out-of-
pocket expenses) play a role in shingles vaccine uptake and
should be mitigated. Pharmacies are playing an important
role in shingles vaccination, partially because they can be
reimbursed by Medicare Part D benefits.29,54 Evidence
suggests some success of pharmacy interventions to
remove barriers to shingles vaccination and increase
shingles vaccination coverage.55–58 Because of Part D
reimbursement structure, convenience of pharmacy loca-
tions and hours, and pharmacists’ established roles as
vaccination providers, pharmacists are in an optimal
position to identify, educate, and vaccinate eligible
patients against shingles.29,54–58 Other comprehensive
strategies for improving shingles vaccination uptake
include use of reminder/recall systems; educational
campaigns; use of standing orders; linking delivery of
shingles vaccine to delivery of other indicated adult
vaccines (e.g., influenza); and routinely assessing patients’
vaccination status.6,35,59–61
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